Cisplatin and Head and Neck Cancer: Understanding Drug Sensitivity
Author Information
Author(s): Welters M J P, Fichtinger-Schepman A M J, Baan R A, Jacobs-Bergmans A J, Kegel A, van der Vijgh W J F, Braakhuis B J M
Primary Institution: Toxicology Division, TNO Nutrition and Food Research Institute
Hypothesis
There is a correlation between platinum content, DNA adduct levels, and drug sensitivity in head and neck cancer.
Conclusion
The study found significant correlations between platinum levels and tumor response to cisplatin therapy.
Supporting Evidence
- Total platinum contents and cisplatin–DNA adduct levels were determined in vivo and in vitro.
- Sensitivity to cisplatin varied three- to sevenfold among cell lines and tumors.
- Significant correlations were found between total platinum levels and tumor response to cisplatin therapy.
- The platinum–AG adduct may be the cytotoxic lesion linked to drug sensitivity.
Takeaway
This study looked at how well a cancer drug works in head and neck cancer by checking how much of the drug gets into the cancer cells and how it affects them.
Methodology
The study used both in vivo xenograft models in mice and in vitro cultured tumor cells to measure platinum content and DNA adduct levels.
Limitations
The study's findings may not fully represent in vivo situations due to differences in sensitivity rankings between cell lines and tumors.
Participant Demographics
The study involved human head and neck squamous cell carcinoma (HNSCC) tumor lines and cell lines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website